26th Mar 2015 08:20
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that its Encruse Ellipta product, or umeclidinium, has been approved for the treatment of chronic obstructive pulmonary disease by the Japanese Ministry of Health, Labour and Welfare.
Additionally, its Duac gel for the treatment of acne vulgaris and its pneumococcal conjugate paediatric vaccine Synflorix were also approved in Japan.
Glaxo expects to launch Encruse Ellipta in Japan during 2015.
Encruse is a once-daily long-acting muscarinic antagonist, which is delivered in the Ellipta inhaler.
Shares in Glaxo are trading down 0.1% at 1,593.00 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline